Featured News Articles: Page 1 of 9

Combination of Electric Fields and Chemotherapy May Be A New Treatment Option for Pleural Mesothelioma Patients

• May 31, 2018
• Nancy Meredith
• Featured News, Research, Treatments

The key to increasing  survival for mesothelioma patients is to kill the cancer cells before they can spread to other organs. Treatment options, including surgery, chemotherapy and radiation, all contribute to a patient’s survival, but many times the prognosis remains unchanged. Now, one company has turned to experimenting with delivering electromagnetic waves to the chest of pleural mesothelioma patients and reports improvements in overall survival when combined with chemotherapy. [...]

Continue reading

ASCO Offers Malignant Pleural Mesothelioma Treatment Guidelines

• February 8, 2018
• Nancy Meredith
• Pleural Mesothelioma, Treatments

he American Society of Clinical Oncology (ASCO) is the world’s leading professional organization for medical professionals caring for cancer patients. The Society has a goal to improve the quality of care in the field of oncology. Now, to assist medical professionals managing patients with malignant pleural mesothelioma, the organization has just released new evidence-based recommendations.

Continue reading

Combination of Liquid Biopsy Tools Improves Results in Detecting Biomarkers, May Lead to Better Selection of Targeted Mesothelioma Treatments

• January 22, 2018
• Nancy Meredith
• For Your Family, Pleural Mesothelioma, Research, Treatments

Researchers continue to look for an effective tool that can be used for the early detection of cancer and to track the effectiveness of treatment. Now, one company reports that by pairing its liquid biopsy analyzer tool with another company’s genetic data analysis tool, the resulting tests proved to be nearly 100% accurate. This is another step in using blood tests to help guide personalized medicine for lung cancer and pleural mesothelioma patients. In a press release prior to the [...]

Continue reading

Mesothelioma Drug Given Promising Innovative Medicine Status in the UK

• January 18, 2018
• Nancy Meredith
• Featured News, Research, Treatments

Boehringer Ingelheim has announced that the UK is following in the footsteps of the U.S. in the latest designation for the company’s drug nintedanib. In December 2016, the U.S. Food and Drug Administration granted orphan drug designation to the investigational cancer drug for the treatment of mesothelioma. Now, the UK Medicine and Healthcare Products Regulatory Agency has designated nintedanib a Promising Innovative Medicine for the treatment of malignant pleural mesothelioma. The PIM [...]

Continue reading

Mesothelioma Patients Hopeful After Anti-Cancer Drug Alectinib Was “Superior” to Crizotinib for Some Lung Cancer Patients

• April 20, 2017
• Nancy Meredith
• Mesothelioma, Treatments

In Dec. 2015 the U.S. Food and Drug Administration approved Alecensa (alectinib) for the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in patients who have progressed on or are intolerant to Xalkori (crizotinib). Now, results from a global phase III clinical trial show alectinib, when used as a first-line treatment, “significantly reduced the risk of disease worsening or death compared to crizotinib in ALK-positive NSCLC patients.” According [...]

Continue reading

• Next